Potassium Iodide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Potassium Iodide
- Potassium Iodide: From Allergic Rhinitis and Upper Respiratory Inflammation to Nasal Cavity Disease
Potassium Iodide: From Allergic Rhinitis and Upper Respiratory Inflammation to Nasal Cavity Disease
One-Sentence Summary
Potassium iodide was originally used for upper respiratory conditions such as allergic rhinitis, vasomotor rhinitis, pharyngitis, the common cold and nasopharyngitis. The TxGNN model predicts it may be effective for nasal cavity disease, but there are no registered clinical trials and only 4 publications, all case reports (mostly veterinary). The prediction therefore rests mainly on the model score and indirect antifungal-related evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, nasopharyngitis (from the knowledge graph; Singapore licence indication text is not available) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium iodide is an established treatment for certain fungal and oomycete infections (for example sporotrichosis, and in veterinary medicine rhinofacial pythiosis and zygomycosis). It is also traditionally used as an expectorant for upper respiratory secretions, and mechanistically it may be applicable to nasal cavity disease.
The retrieved papers describe nasal or rhinofacial mycotic infections in sheep and horses, plus a single human case of nasofacial zygomycosis that responded rapidly to potassium iodide. This offers plausible, indirect support. However, it does not come from controlled human studies of nasal cavity disease in general. The very high TxGNN score is a model prediction only and is not proof of benefit.
Other predicted indications (for example acute laryngopharyngitis, laryngitis and tracheal disease) are closer to the original upper respiratory uses, but they have even less supporting evidence. Several lower-ranked predictions, such as faucial diphtheria, cervical disc degenerative disorder and headache disorder, have no identifiable mechanistic basis and are likely model artefacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34902797 | 2022 | Case report (veterinary, sheep) | Journal de mycologie medicale | Successful potassium iodide treatment of rhinofacial pythiosis, an oomycete infection of the nasal cavity and hard palate |
| 39576399 | 2024 | Case report (veterinary, horse) | Veterinary research communications | Mycotic rhinitis caused by Aspergillus fumigatus treated with topical clotrimazole plus oral potassium iodide |
| 10976304 | 2000 | Case report (veterinary, horse) | Journal of the American Veterinary Medical Association | Pseudallescheria boydii infection of the nasal cavity; treatment included intranasal miconazole and intravenous sodium iodide |
| 7997795 | 1994 | Case report (human) | Revista do Instituto de Medicina Tropical de Sao Paulo | Nasofacial zygomycosis in a 64-year-old woman, with rapid response to potassium iodide |
All four are case reports. None is a controlled study.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08899P | PEDITRACE CONCENTRATE FOR PARENTERAL INFUSION | Injection | Not available |
| SIN15302P | ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION | Infusion, solution concentrate | Not available |
| SIN14341P | Nutritrace Concentrate for solution for infusion | Infusion, solution concentrate | Not available |
The three registered products are injectable or infusion concentrates. Their forms are not suited to treating nasal disease, so route compatibility for the predicted indication has not been established.
Safety Considerations
Contraindication signals from the knowledge graph (these are graph associations, not package insert text). The listed conditions include:
- Thyroid: hypothyroidism, myxedema, congenital hypothyroidism
- Cardiovascular and renal: hypertension, kidney disease
- Liver and digestive: liver failure, liver disease, gallbladder disease, pancreatitis, peptic ulcer disease, inflammatory bowel disease
- Respiratory: chronic obstructive pulmonary disease
- Neuropsychiatric: epilepsy, anxiety disorder, psychotic disorder, schizoaffective disorder
- Metabolic and other: diabetes mellitus, diabetic ketoacidosis, porphyria, thrombocytopenia, dermatitis herpetiformis
Drug interactions: 45 interactions were identified; the 20 listed in the data are summarised here.
- Major: ACE inhibitors (benazepril, captopril, enalapril, lisinopril, moexipril, perindopril, quinapril), angiotensin receptor blockers (olmesartan, valsartan, azilsartan medoxomil, losartan, telmisartan), and trimethoprim. These are likely linked to a risk of raised potassium.
- Moderate: NSAIDs (ketorolac, ibuprofen, diclofenac, oxaprozin, naproxen), aliskiren and tolvaptan.
Other signals from the literature: one historical report describes potassium iodide poisoning presenting as a laryngeal crisis. Iodides can also cause hypersensitivity or urticarial reactions, and thyroid function effects are a recognised concern.
Package insert warnings and contraindications for the Singapore products were not available. Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is limited to a few case reports, mostly in animals, with no registered trials and no controlled human data. The high TxGNN score is a prediction only. The registered Singapore products are parenteral trace-element or nutrition concentrates and are not suitable for treating nasal disease. The drug also has a notable interaction and contraindication profile.
To proceed, the following is needed:
- Mechanism of action data for potassium iodide
- Package insert warnings and contraindications for the Singapore products (currently a blocking gap for safety screening)
- Controlled human studies, or at least larger human case series, in a defined nasal condition such as fungal rhinosinusitis
- A route and formulation assessment, since no nasal or oral product is currently registered
- A safety plan covering thyroid function, potassium monitoring and hypersensitivity, especially with ACE inhibitors and angiotensin receptor blockers
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.